Welcome - Home - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Viewing report Order by Fax Printer Friendly PDF Brochure Send to Friend Enquire before Buying Electronic Hard Copy The Pharmaceutical Market: Philippines Espicom Business Intelligence Ltd, March 2009, Pages: 62   Description     Table of Contents        Enquire before Buying    Send to a Friend   Changes to be brought by the controversial Cheaper Medicine Bill will impact the Philippines pharmaceutical market in a number of areas, including IP laws, competition and drug price control mechanisms. This report is ideal for executives wanting to understand the key drivers in the pharmaceutical market and have access to a wealth of statistical data, including five-year market projections. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year. Changes to be brought by the controversial Cheaper Medicine Bill will impact the Philippines pharmaceutical market in a number of areas, including IP laws, competition and drug price control mechanisms. The market is expected to be especially volatile in the short term. The government has been criticised in the past for not doing enough to promote generics and has recently stepped up its efforts, launching Project 100 in 2008 for example, which promises to offer cheap generics at 100 public hospitals around the country. Parallel imports have increased and the government has urged retailers and wholesalers to stock more generics, as part of its campaign to reduce the price of many essential medicines. The Philippines is one of the poorer countries in the ASEAN region, with GDP per capita estimated at just US$1,520 in 2009. Health expenditure is also low, both in absolute terms and as a percentage of GDP. The country attracts a degree of overseas aid, although it is reportedly a difficult place in which to undertake healthcare projects. Administration of the health sector is highly devolved to local government units. This can make planning and co-ordination difficult. Between 50% and 60% of healthcare expenditure and provision is in the private sector. An exodus of medical staff overseas in pursuit of better wages and working conditions has put severe pressure on healthcare services. The Philippines has around 1.1 doctors per thousand population. The Philippine pharmaceutical market is valued at US$1.4 billion in 2008, equal to nearly US$15 per capita. In terms of the overall market this is comparable to Pakistan and Thailand, and in per capita terms similar to China and Iran. Customers who bought this item also bought Philippines Pharmaceuticals & Healthcare Report Q3 2007 Philippines Pharmaceuticals and Healthcare Report Q3 2008 Philippines Phamaceuticals & Healthcare Report Q1 2008 Philippines Pharmaceuticals and Healthcare Report Q1 2009 Philippines Pharmaceuticals and Healthcare Report Q4 2008 Philippines Pharmaceuticals and Healthcare Report Q2 2009 The Medical Device Market: Philippines The Pharmaceutical Market: Slovakia OTC Healthcare in the Philippines to 2010 Philippines Pharmaceuticals and Healthcare Report Q2 2008 Executive Report on Strategies in Philippines The Pharmaceutical Market: Peru

		Top of page

All rights reserved. � Copyright 2009 Research and Markets    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster